中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

24 records (took 0.028 seconds)

    METHOD OF INDUCING AN IMMUNE RESPONSE BY ADMINISTERING WDRPUH EPITOPE PEPTIDES
    2.
    发明申请
    METHOD OF INDUCING AN IMMUNE RESPONSE BY ADMINISTERING WDRPUH EPITOPE PEPTIDES 审中-公开
    通过管理WDRPUH EPITOPE肽诱导免疫应答的方法

    公开(公告)号：US20150315239A1

    公开(公告)日：2015-11-05

    申请号：US14805424

    申请日：2015-07-21

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC: C07K7/06 ,  A61K39/00

    CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K38/1764 ,  A61K39/0011 ,  C07K14/47 ,  C07K14/4748 ,  C12N5/0638 ,  C12N5/0639

    Abstract: The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.

    Abstract translation: 本发明提供了含有SEQ ID NO：1,2,3,4，16，17，30，31，34，36，37，40，41，45，49，55，57和61的氨基酸序列的肽 ，以及含有上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失，插入或添加，但仍具有细胞毒性T细胞诱导性。 本发明还提供了用于治疗或预防肿瘤的药物，其含有这些肽的药物。 本发明的肽也可以用作疫苗。

    UBE2T peptides and vaccines containing the same
    4.
    发明授权
    UBE2T peptides and vaccines containing the same 有权

    公开(公告)号：US11266729B2

    公开(公告)日：2022-03-08

    申请号：US16120102

    申请日：2018-08-31

    Applicant: OncoTherapy Science, Inc.

    Inventor： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC: A61K39/00 ,  C12N5/0783 ,  C12N5/078 ,  C07K16/40 ,  A61K31/7088 ,  C12N9/00 ,  G01N33/574

    Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

    UBE2T peptides and vaccines containing the same
    7.
    发明授权
    UBE2T peptides and vaccines containing the same 有权

    公开(公告)号：US10092634B2

    公开(公告)日：2018-10-09

    申请号：US14400169

    申请日：2013-09-09

    Applicant: OncoTherapy Science, Inc.

    Inventor： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC: A61K39/00 ,  A61K31/7088 ,  C12N9/00 ,  C07K16/40 ,  G01N33/574

    Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that elicit CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

    TOPK PEPTIDES AND VACCINES INCLUDING THE SAME
    9.
    发明申请
    TOPK PEPTIDES AND VACCINES INCLUDING THE SAME 有权
    TOPK PEPTIDES和疫苗，包括它们

    公开(公告)号：US20140255437A1

    公开(公告)日：2014-09-11

    申请号：US14353261

    申请日：2012-10-25

    Applicant: c/o ONCOTHERAPY SCIENCE, INC.

    Inventor： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama

    IPC: A61K39/00 ,  C07K16/18 ,  C07K7/06

    CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K39/0005 ,  A61K2039/5154 ,  A61K2039/572 ,  C07K7/06 ,  C07K14/4748 ,  C07K16/18 ,  C07K16/40 ,  C07K2317/34 ,  C12N9/12 ,  C12N9/1205 ,  C12Y207/12002 ,  G01N33/505 ,  G01N33/574

    Abstract: The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.

    Abstract translation: 本发明提供了源自TOPK的分离的表位肽，其免疫原性片段具有诱导细胞毒性T淋巴细胞（CTL）的能力，因此适用于癌症免疫治疗，更特别地，作为癌症疫苗。 本发明的肽包括包括TOPK衍生的氨基酸序列和其修饰形式的两种肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，只要这些修饰版本具有CTL 诱导性。 还提供了编码任何前述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物组合物。 本发明的肽，多核苷酸和药物组合物在治疗和预防多种癌症中的任一者或两者中都具有特别的用途。

Patent Agency Ranking